Reiss Peter D, Min Danxi, Leung Mei Y
St John's Laboratory, London, SE8 5RT, UK.
St John's Laboratory, London, SE8 5RT, UK ; PeproTech EC Ltd, London, W6 8LL, UK.
F1000Res. 2014 Nov 5;3:266. doi: 10.12688/f1000research.5668.1. eCollection 2014.
Commercial research antibodies are the most commonly used product in the life science tools market, and their applications represent a significant investment of time and resources for researchers. Frequently however, the quality of antibodies does not meet the expectations of consumers, causing loss of valuable time and money. This can delay research efforts and scientific discovery, or even lead to false, irreproducible results to be published in the scientific literature. This raises the question of whether there should be universal standards for validating antibodies. During the 1 (st) International Antibody Validation Forum, hosted by St John's Laboratory Ltd on October 15 (th) 2014 at Queen Mary University of London, scientists from academia and industry presented data highlighting quality issues arising from lack of antibody validation. While the forum identified significant current problems in the antibody market, it also discussed future opportunities for improved quality and transparency by encouraging data disclosure and data sharing. This article highlights the key issues and conclusions reached at the forum.
商业研究抗体是生命科学工具市场中最常用的产品，其应用对研究人员来说意味着大量的时间和资源投入。然而，抗体质量常常无法满足消费者的期望，造成宝贵时间和金钱的损失。这可能会延误研究工作和科学发现，甚至导致错误的、无法重复的结果发表在科学文献中。这就引发了一个问题：是否应该有验证抗体的通用标准。 2014年10月15日，由圣约翰实验室有限公司在伦敦玛丽女王大学主办的第一届国际抗体验证论坛上，来自学术界和业界的科学家展示了数据，突出了因缺乏抗体验证而产生的质量问题。虽然该论坛指出了当前抗体市场存在的重大问题，但也讨论了通过鼓励数据披露和数据共享来提高质量和透明度的未来机遇。本文重点介绍了该论坛的关键问题和达成的结论。
